Patents by Inventor Wayne A. Marasco

Wayne A. Marasco has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Glucocorticoid-induced tumor necrosis factor receptor (GITR) antibodies and methods of use thereof
    Patent number: 11046777
    Abstract: The present invention comprises human monoclonal antibodies that bind to GITR (also known as glucocorticoid-induced tumor necrosis factor receptor). Binding of the invented antibody to GITR inhibits binding of its ligand, GITR-L, and can be used to treat cancer.
    Type: Grant
    Filed: July 24, 2017
    Date of Patent: June 29, 2021
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Wayne A. Marasco, Quan Karen Zhu
  • ENGINEERED CELLS, T CELL IMMUNE MODULATING ANTIBODIES AND METHODS FOR USING THE SAME
    Publication number: 20210163570
    Abstract: This invention is directed to engineered cells and methods for using the same. In embodiments, the engineered cell comprises a nucleic acid encoding a chimeric antigen receptor and a polypeptide, wherein the chimeric antigen receptor is specific for two or more antigens on the surface of a cancer cell, and wherein the polypeptide comprises an antibody or fragment thereof that can be secreted from the engineered cell.
    Type: Application
    Filed: March 14, 2019
    Publication date: June 3, 2021
    Inventors: Wayne A. Marasco, Quan Karen Zhu, Emily Kuiper
  • MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS NEUTRALIZING ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20210147513
    Abstract: The present invention provides antibodies that neutralize MERS-CoV and methods of use thereof. The invented antibody is used to treat MERS-CoV infections and symptoms thereof.
    Type: Application
    Filed: October 28, 2020
    Publication date: May 20, 2021
    Inventors: Wayne A. MARASCO, Xianchun TANG
  • GLUCOCORTICOID-INDUCED TUMOR NECROSIS FACTOR RECEPTOR (GITR) ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20210101989
    Abstract: The present invention comprises human monoclonal antibodies that bind to GITR (also known as glucocorticoid-induced tumor necrosis factor receptor). Binding of the invented antibody to GITR inhibits binding of its ligand, GITR-L, and can be used to treat cancer.
    Type: Application
    Filed: July 24, 2017
    Publication date: April 8, 2021
    Inventors: Wayne A. Marasco, Quan Karen Zhu
  • FC VARIANT COMPOSITIONS AND METHODS OF USE THEREOF
    Publication number: 20210070860
    Abstract: The present invention provides compositions and methods for augmenting antibody mediate receptor signaling.
    Type: Application
    Filed: March 21, 2019
    Publication date: March 11, 2021
    Inventors: Wayne A. Marasco, Quan Karen Zhu, Matthew R. Chang
  • CHIMERIC ANTIGEN RECEPTORS AND METHODS OF USE THEREOF
    Publication number: 20210061877
    Abstract: The present invention provides chimeric antigen receptors, cells expressing same and methods of using same for treatment various disorders such as cancer.
    Type: Application
    Filed: August 6, 2020
    Publication date: March 4, 2021
    Inventor: Wayne A. Marasco
  • Flavivirus neutralizing antibodies and methods of use thereof
    Patent number: 10899825
    Abstract: The present invention provides antibodies that neutralize flavivirus and methods of use thereof. These antibodies are derived from mAbl 1 which recognizes West Nile virus E protein and is cross-reactive with members of the flavivirus family, including Denge virus. The antibodies of the present invention prevent antibody-dependent enhancement of a viral infection by having a modified Fc region that does not bind to the Fcy receptor. The invented antibody is used to treat flaviviral infections and symptoms thereof.
    Type: Grant
    Filed: July 17, 2019
    Date of Patent: January 26, 2021
    Assignee: DANA-FARBER CANCER INSTITUTE, INC.
    Inventor: Wayne A. Marasco
  • HUMANIZED CC CHEMOKINE RECEPTOR 4 (CCR4) ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20210000950
    Abstract: The present invention provides humanized monoclonal antibodies, bi-specific antibodies, antibody conjugates, and fusion proteins that bind to the chemokine receptor CCR4. This antibody is derived from CCR4-IgG1 and recognizes the same epitope. This antibody contains either an IgG4 or a stabilized IgG4 in order to improve binding efficiency and reduce in vivo Fab arm exchange. Binding of the antibodies disclosed herein to CCR4 inhibits ligand-mediated activities and is used to treat symptoms of cancer.
    Type: Application
    Filed: June 2, 2020
    Publication date: January 7, 2021
    Inventors: Wayne A. Marasco, Quan Zhu, De-Kuan Chang
  • Composition and methods of treating B cell disorders
    Patent number: 10870694
    Abstract: The present invention comprises methods of using a humanized monoclonal antibody that binds to the human immunoglobulin heavy chain variable region germline gene VH1-69 to treat B-cell disorders.
    Type: Grant
    Filed: September 5, 2017
    Date of Patent: December 22, 2020
    Assignee: Dana Farber Cancer Institute, Inc.
    Inventor: Wayne A. Marasco
  • Chimeric antigen receptors specific for carbonic acid anhydrase IX
    Patent number: 10870705
    Abstract: The present invention provides chimeric antigen receptor cells specific for carbonic anhydrase IX (CAIX) and methods of using same for treatment of CAIX expressing cancers such as renal cell carcinoma.
    Type: Grant
    Filed: December 21, 2015
    Date of Patent: December 22, 2020
    Assignee: DANA-FARBER CANCER INSTITUTE, INC.
    Inventor: Wayne A. Marasco
  • HUMAN MONOCLONAL ANTI-PD-L1 ANTIBODIES AND METHODS OF USE
    Publication number: 20200385482
    Abstract: The present invention comprises human monoclonal antibodies that bind to PD-L1 (also known as programmed death ligand 1 or B7H1). Binding of the invented antibody to PD-L1 inhibits binding to its receptor, PD1 (programmed death 1), and ligand-mediated activities and can be used to treat cancer and chronic viral infections.
    Type: Application
    Filed: March 30, 2020
    Publication date: December 10, 2020
    Inventors: Wayne A. Marasco, Jianhua Sui
  • Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof
    Patent number: 10851155
    Abstract: The present invention provides antibodies that neutralize MERS-CoV and methods of use thereof. The invented antibody is used to treat MERS-CoV infections and symptoms thereof.
    Type: Grant
    Filed: November 19, 2018
    Date of Patent: December 1, 2020
    Assignee: DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Wayne A. Marasco, Xianchun Tang
  • METHODS OF MEDIATING CYTOKINE EXPRESSION WITH ANTI CCR4 ANTIBODIES
    Publication number: 20200369775
    Abstract: The present disclosure provides methods of modulating regulatory T-cell activity and function.
    Type: Application
    Filed: February 10, 2020
    Publication date: November 26, 2020
    Inventor: Wayne A. MARASCO
  • Conserved hemagglutinin epitope, antibodies to the epitope, and methods of use
    Patent number: 10774134
    Abstract: Disclosed are antibodies that bind to the stem region of influenza hemagglutinin in the neutral pH conformation, hemagglutinin epitopes to the stem region, and methods of making and using both.
    Type: Grant
    Filed: June 20, 2018
    Date of Patent: September 15, 2020
    Assignees: Dana-Farber Cancer Institute, Inc., Burnham Institute for Medical Research
    Inventors: Wayne A. Marasco, Jianhua Sui, Robert C. Liddington
  • GLUCOCORTICOID-INDUCED TUMOR NECROSIS FACTOR RECEPTOR (GITR) ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20200261578
    Abstract: The present invention comprises human monoclonal antibodies that bind to GITR (also known as glucocorticoid-induced tumor necrosis factor receptor) Binding of the invented antibody to GITR inhibits binding of its ligand, GITR-L, and can be used to treat cancer.
    Type: Application
    Filed: November 4, 2019
    Publication date: August 20, 2020
    Inventors: Wayne A. Marasco, Chen Xu, De-Kuan Chang
  • Humanized CC chemokine receptor 4 (CCR4) antibodies and methods of use thereof
    Patent number: 10675349
    Abstract: The present invention provides humanized monoclonal antibodies, bi-specific antibodies, antibody conjugates, and fusion proteins that bind to the chemokine receptor CCR4. This antibody is derived from CCR4-IgG1 and recognizes the same epitope. This antibody contains either an IgG4 or a stabilized IgG4 in order to improve binding efficiency and reduce in vivo Fab arm exchange. Binding of the antibodies disclosed herein to CCR4 inhibits ligand-mediated activities and is used to treat symptoms of cancer.
    Type: Grant
    Filed: October 6, 2015
    Date of Patent: June 9, 2020
    Assignee: DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Wayne A. Marasco, Quan Zhu, De-Kuan Chang
  • CARBONIC ANHYDRASE IX (G250) ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20200165357
    Abstract: The invention provides scFv antibodies and monoclonal antibodies that bind to and decrease an activity of Carbonic Anhydrase IX (G250). Also provided are the methods of treating and/or preventing cancer, such as renal clear cell cancer. Also provided are methods of identifying a carbonic anhydrase IX (G250) protein. The invention additionally provides methods of modifying immune effector cells, and the immune effector cells modified thereby.
    Type: Application
    Filed: October 21, 2019
    Publication date: May 28, 2020
    Inventors: Wayne A. Marasco, Agnes Lo, Chen Xu, Quan Zhu
  • Human monoclonal anti-PD-L1 antibodies and methods of use
    Patent number: 10604581
    Abstract: The present invention comprises human monoclonal antibodies that bind to PD-L1 (also known as programmed death ligand 1 or B7H1). Binding of the invented antibody to PD-L1 inhibits binding to its receptor, PD1 (programmed death 1), and ligand-mediated activities and can be used to treat cancer and chronic viral infections.
    Type: Grant
    Filed: November 22, 2017
    Date of Patent: March 31, 2020
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Wayne A. Marasco, Jianhua Sui
  • Humanized monoclonal antibodies and methods of use
    Patent number: 10584172
    Abstract: The present invention comprises a humanized monoclonal antibody that binds to the chemokine receptor CCR4. This antibody is derived from Mab 1567 and recognizes the same epitope. Binding of the invented antibody to CCR4 inhibits ligand-mediated activities and is used to treat symptoms of cancer. Moreover, the antibody is used in combination with vaccines to suppress the activity of regulatory T cells.
    Type: Grant
    Filed: August 12, 2016
    Date of Patent: March 10, 2020
    Assignees: DANA FARBER CANCER INSTITUTE, INC., THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
    Inventors: Wayne Marasco, Jianhua Sui, Quan Zhu, Thomas Kupper
  • FLAVIVIRUS NEUTRALIZING ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20200062830
    Abstract: The present invention provides antibodies that neutralize flavivirus and methods of use thereof. These antibodies are derived from mAbl 1 which recognizes West Nile virus E protein and is cross-reactive with members of the flavivirus family, including Denge virus. The antibodies of the present invention prevent antibody-dependent enhancement of a viral infection by having a modified Fc region that does not bind to the Fcy receptor. The invented antibody is used to treat flaviviral infections and symptoms thereof.
    Type: Application
    Filed: July 17, 2019
    Publication date: February 27, 2020
    Inventor: Wayne A. Marasco